首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   114654篇
  免费   9567篇
  国内免费   5033篇
耳鼻咽喉   279篇
儿科学   2068篇
妇产科学   1133篇
基础医学   20922篇
口腔科学   2470篇
临床医学   9355篇
内科学   28352篇
皮肤病学   1775篇
神经病学   4205篇
特种医学   2222篇
外国民族医学   12篇
外科学   6424篇
综合类   16907篇
现状与发展   28篇
预防医学   8600篇
眼科学   1527篇
药学   12378篇
  30篇
中国医学   4841篇
肿瘤学   5726篇
  2023年   1324篇
  2022年   2059篇
  2021年   4070篇
  2020年   3504篇
  2019年   3813篇
  2018年   3655篇
  2017年   3609篇
  2016年   4054篇
  2015年   4359篇
  2014年   6962篇
  2013年   7890篇
  2012年   6883篇
  2011年   7542篇
  2010年   5951篇
  2009年   5732篇
  2008年   5725篇
  2007年   5809篇
  2006年   5300篇
  2005年   4685篇
  2004年   4015篇
  2003年   3560篇
  2002年   2961篇
  2001年   2719篇
  2000年   2276篇
  1999年   1939篇
  1998年   1817篇
  1997年   1662篇
  1996年   1294篇
  1995年   1508篇
  1994年   1341篇
  1993年   1143篇
  1992年   1066篇
  1991年   905篇
  1990年   790篇
  1989年   616篇
  1988年   618篇
  1987年   505篇
  1986年   435篇
  1985年   877篇
  1984年   766篇
  1983年   585篇
  1982年   568篇
  1981年   439篇
  1980年   380篇
  1979年   319篇
  1978年   273篇
  1977年   203篇
  1976年   197篇
  1975年   169篇
  1974年   139篇
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
1.
2.
背景 致密性骨炎(OCI)和其他疾病有时难以鉴别,探讨血清骨转换生化标志物可为OCI的鉴别诊断提供依据。 目的 探索女性OCI患者的血清骨转换生化标志物的水平变化及临床意义。 方法 回顾性选取2013年6月至2022年2月在北京积水潭医院门诊及住院诊断为OCI的61例女性患者作为观察组,年龄15~50岁,平均(33.8±6.6)岁,病程2周~15年。选择同期61例女性体检健康者作为对照组,年龄15~48岁,平均(35.6±7.6)岁。比较两组一般临床资料和血清骨转换生化标志物水平,并对血清骨转换生化标志物与病情相关指标进行相关性分析。 结果 观察组血清白蛋白(45.4±2.9)g/L低于对照组(46.5±2.8)g/L(t=2.190,P<0.05)。血清骨转换生化标志物比较结果显示,观察组血清1型胶原羧基末端肽β特殊序列(β-CTX)〔0.28(0.23,0.37)μg/L〕、N-端骨钙素(OC)〔13.1(11.2,16.2)μg/L〕、25-羟维生素D3〔25-(OH)VD3〕〔(14.1±5.1)μg/L〕低于对照组〔0.36(0.29,0.48)μg/L,15.6(13.7,17.3)μg/L,(17.5±6.6)μg/L〕(Z=-2.983、-3.255,t=3.081,P<0.05)。长病程亚组OC水平〔14.6(12.4,18.5)μg/L〕高于短病程亚组〔11.7(10.2,14.0)μg/L〕(Z=-2.407,P<0.05)。多孕亚组β-CTX〔0.25(0.22,0.32)μg/L〕、OC水平〔12.2(10.3,15.0)μg/L〕低于非多孕亚组〔0.33(0.26,0.44)μg/L、13.4(12.0,18.8)μg/L〕(Z=-2.486、-1.897,P<0.05)。相关性分析显示,观察组血清1型前胶原氨基端延长肽(tP1NP)与妊娠次数、生产次数均呈负相关(rs=-0.276、-0.298,P<0.05),OC与体质指数(BMI)、视觉模拟评分法(VAS)评分、妊娠次数均呈负相关(rs=-0.284、-0.374、-0.360,P<0.05),25-(OH)VD3水平与BMI呈正相关(rs=0.275,P<0.05)。 结论 女性OCI患者血清OC、β-CTX水平明显降低,可为鉴别其他疾病提供依据;血清OC水平可以反映OCI患者的严重程度,同时OC水平与患者妊娠次数相关;tP1NP与妊娠次数、生产次数相关。  相似文献   
3.
The circadian rhythm in humans is determined by the central clock located in the hypothalamus’s suprachiasmatic nucleus, and it synchronizes the peripheral clocks in other tissues. Circadian clock genes and clock-controlled genes exist in almost all cell types. They have an essential role in many physiological processes, including lipid metabolism in the liver, regulation of the immune system, and the severity of infections. In addition, circadian rhythm genes can stimulate the immune response of host cells to virus infection. Hepatitis B virus (HBV) infection is the leading cause of liver disease and liver cancer globally. HBV infection depends on the host cell, and hepatocyte circadian rhythm genes are associated with HBV replication, survival, and spread. The core circadian rhythm proteins, REV-ERB and brain and muscle ARNTL-like protein 1, have a crucial role in HBV replication in hepatocytes. In addition to influencing the virus’s life cycle, the circadian rhythm also affects the pharmacokinetics and efficacy of antiviral vaccines. Therefore, it is vital to apply antiviral therapy at the appropriate time of day to reduce toxicity and improve the effectiveness of antiviral treatment. For these reasons, understanding the role of the circadian rhythm in the regulation of HBV infection and host responses to the virus provides us with a new perspective of the interplay of the circadian rhythm and anti-HBV therapy. Therefore, this review emphasizes the importance of the circadian rhythm in HBV infection and the optimization of antiviral treatment based on the circadian rhythm-dependent immune response.  相似文献   
4.
Breast core biopsies are a standard component of the triple approach that includes clinical examination, imaging and tissue sampling. Conventional cores, diagnostic vacuum assisted biopsy and vacuum assisted excisions are established methods for sampling and managing breast lesions. It is important to be aware of the potential pitfalls in the technical handling and interpretation of the limited core biopsy samples. Here, we present a clinically oriented, well illustrated overview of the common diagnostic pitfalls based on the author's diagnostic and second opinion practice, emphasize the value of clinicopathological correlation and provide histological tips and clues with useful immunohistochemistry to aid the reporting pathologists in their daily interpretation of breast core biopsies.  相似文献   
5.
IntroductionMonoclonal antibody therapy has been reported to be highly effective for preventing hospitalisation and severe cases in patients with Coronavirus Disease 2019 (COVID-19). However, since the drug is not readily available, it is important to rapidly and appropriately identify high-risk patients who can benefit most from therapy. Therefore, we designed a risk scoring system to identify at-risk COVID-19 patients in our region during the largest surge of COVID-19, from July to September 2021.MethodsAccording to the risk scores, confirmed COVID-19 patients were introduced to receive REGN-CoV-2 to our hospital by regional health centre from 18th August (Term 3). The primary outcome was the comparison of the number of hospitalisation and severe condition with other periods, the 4th wave (Term 1) and the early part of the 5th wave (Term 2) in Japan.ResultsDuring Term 3, 115 patients were stratified with the scoring system and administered REGN-COV-2. The number of hospitalisation vs severe cases were 60 (5.2%) vs 14 (1.2%), 8 (1.5%) vs 3 (0.6%) and 21 (1.2%) vs 2 (0.1%), in term 1, 2 and 3, respectively. Among those aged <60 years, compared with term 1, the relative risk of hospitalisation and severe condition were 0.25 (95% CI: 0.12–0.53) and 0.10 (95% CI: 0.01–0.80), respectively, in term 3. Drug adverse events were fever (3: 2.6%), headache (1: 0.9%) and neck rash (1: 0.9%), all events were resolved within 24 h wth no serious adverse event.ConclusionsThe administration of monoclonal antibody therapy using a risk scoring system significantly reduced the number of hospitalisation and disease severity of COVID-19 without any serious adverse events and avoided regional medical collapse.  相似文献   
6.
目的 探讨滋肾育胎丸加减方预防抗磷脂抗体(ACA)阳性者不良妊娠结局的效果及机制研究。方法 选取2016年2月至2019年2月我院收治的89例ACA阳性,先兆性流产或有习惯性流产(RSA)史患者,将采用西医治疗的40例作为对照组,将采用西医联合滋肾育胎丸加减方治疗的49例作为观察组,比较两组中医证候疗效、中医证候积分、ACA-IgA、ACA-IgM、ACA-IgG、凝血指标[血小板聚集功能(PAF)、活化蛋白C(PC)、抗凝血酶(AT)、纤溶酶原激活抑制物-1(PAI-1)]、Th1/Th2细胞因子[干扰素γ(IFN-γ)、白介素-2(IL-2)、白介素-4(IL-4)、白介素-10(IL-10)]、妊娠结局、安全性。结果 治疗2周后检测ACA,观察组2例未降低,对照组11例未降低,观察组未降低患者占比低于对照组(P<0.05);观察组总有效率100.00%高于对照组85.00%(P<0.05);观察组治疗4周、7周后中医证候积分低于对照组(P<0.05);观察组治疗4周、7周后ACA-IgA、ACA-IgM、ACA-IgG低于对照组(P<0.05);观察组治疗4周、7周后PAF、PAI-1低于对照组,PC、AT高于对照组(P<0.05);观察组治疗4周、7周后IFN-γ、IL-2低于对照组,IL-4、IL-10高于对照组(P<0.05);观察组活产率95.92%高于对照组80.00%(P<0.05);组间不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 动态监测ACA对滋肾育胎丸加减方精准应用具有指导意义,指导滋肾育胎丸加减方通过调理脏腑、气血、经络功能,改善先兆性流产或有RSA史患者临床症状及凝血因子指标,降低ACA水平,并可改善患者免疫耐受功能,提高胎儿活产率,且安全性高。  相似文献   
7.
ABSTRACT

Objective: Dry eye is reported to be associated with several neurological diseases. The aim of this study is to evaluate the patients with hemiplegia after stroke for dry eye and compare their results with a control group.

Materials and methods: Forty-five patients with hemiplegia and 45 individuals as the control group were included in the study. Tear function tests (Schirmer and tear breakup time) and a dry eye questionnaire for dry eye symptoms (ocular surface disease index) were performed and the results of the two groups were compared.

Results: Schirmer test results were significantly lower in the post-stroke hemiplegia group compared to the control group (11.3 ± 8.2 mm and 20.6 ± 11.6 mm, respectively, p < .001). Tear breakup time results were significantly lower in the post-stroke hemiplegia group compared to the control group (7.9 ± 3.1 s and 12.1 ± 4.3 s, respectively, p < .001). Ocular surface disease index scores were not significantly different between hemiplegia and control groups (21.6 ± 20.0 and 19.8 ± 13.9, respectively, p = .635). Schirmer scores lower than 10 mm (60% and 30%, p < .001) and tear breakup time results lower than 10 s (65.6% and 28.9%, p < .001) were also higher in the hemiplegia group compared to control group.

Conclusion: We found lower Schirmer test and tear breakup time results and similar OSDI scores in hemiplegia patients compared to controls. Hemiplegia patients may have dry eye without typical symptoms. This should be taken into consideration in the follow-up and rehabilitation of post-stroke hemiplegia patients.  相似文献   
8.
  1. The common marmoset (Callithrix jacchus) is a useful experimental animal to evaluate the pharmacokinetics of drug candidates. Cytochrome P450 (P450) 2B enzyme in marmoset livers has been identified; however, only limited information on the enzymatic properties and distribution has been available.

  2. Marmoset P450 2B6 amino acids showed high sequence identities (>86%) with those of primates including humans and cynomolgus monkeys. Phylogenetic analysis using amino acid sequences indicated that marmoset P450 2B6 was closer to human and cynomolgus monkey P450 2B6 than to P450 2B orthologs of other species, including pigs, dogs, rabbits and rodents.

  3. Quantitative polymerase chain reaction analysis using specific primers showed P450 2B6 mRNA predominantly expressed in livers among the five marmoset tissues, similar to those of humans and cynomolgus monkeys.

  4. Marmoset P450 2B6 heterologously expressed in Escherichia coli membranes oxidized 7-ethoxycoumarin, pentoxyresorufin, propofol and testosterone, at roughly similar rates to those of humans and/or cynomolgus monkeys. A high capacity of marmoset P450 2B6 with propofol 4-hydroxylation (at low ionic strength conditions) with a low Km value was relatively comparable to that for marmoset livers.

  5. These results collectively indicated a high propofol 4-hydroxylation activity of P450 2B6 expressed in marmoset livers.

  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号